BPC-157 is an experimental peptide, and it has not been approved by the FDA to diagnose, treat, cure, or prevent any disease
During freeze-drying, the peptides are gently frozen and placed under low pressure so the water turns straight from ice into vapor
Published research indicates that this protection is substantial
Most anecdotal reports do not include confirmed diagnoses, standardized treatment plans, control groups, or long-term follow-up
Preclinical data support fat loss and metabolic benefits
This characteristic allows exploratory evaluation of oral administration, although current data indicate that oral bioavailability is presumed lower than parenteral routes